PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PTCT PTC Therapeutics Inc.

盘后交易 05-09 18:09:50 EDT

31.05

-0.09

-0.29%

盘后31.05

+0.000.00%

16:20 EDT

最高31.39	最低30.79	成交量82.25万
今开31.14	昨收31.14	日振幅1.92%
总市值23.81亿	流通市值17.58亿	总股本7,670万
成交额2,556万	换手率1.45%	流通股本5,662万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PTCT","market":"US","secType":"STK","nameCN":"PTC Therapeutics Inc.","latestPrice":31.05,"timestamp":1715284800000,"preClose":31.14,"halted":0,"volume":822545,"hourTrading":{"tag":"盘后","latestPrice":31.05,"preClose":31.05,"latestTime":"16:20 EDT","volume":285370,"amount":8860738.5,"timestamp":1715286000446},"delay":0,"floatShares":56620856,"shares":76696785,"eps":-7.676254,"marketStatus":"盘后交易","marketStatusCode":4,"change":-0.09,"latestTime":"05-09 18:09:50 EDT","open":31.14,"high":31.3875,"low":30.79,"amount":25562348.588935,"amplitude":0.019188,"askPrice":34.92,"askSize":100,"bidPrice":30,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-7.676254,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1715299200000},"adr":0,"listingDate":1371700800000,"adjPreClose":31.14,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":31.05,"preClose":31.05,"latestTime":"16:20 EDT","volume":285370,"amount":8860738.5,"timestamp":1715286000446},"volumeRatio":1.171967},"requestUrl":"/m/hq/s/PTCT/tweets","defaultTab":"tweets","newsList":[{"id":"2432982490","title":"Ptc Therapeutics, Inc.2024财年第一财季实现净利润-91.58百万美元，同比增加34.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432982490","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432982490?lang=zh_cn&edition=full","pubTime":"2024-05-03 00:25","pubTimestamp":1714667156,"startTime":"0","endTime":"0","summary":"3月31日，Ptc Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-91.58百万美元，同比增加34.12%；其中营业收入为2.10亿美元，同比减少4.55%，每股基本收益为-1.20美元。从资产负债表来看，Ptc Therapeutics, Inc.总负债26.84亿美元，其中短期债务16.52百万美元，资产负债比为0.67，流动比率为2.04。机构评级：截至2024年3月31日，当前有12家机构对Ptc Therapeutics, Inc.目标价做出预测，其中目标均价为29.50美元，其中最低目标价为16.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405030026088b6d98e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405030026088b6d98e5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431865610","title":"Ptc Therapeutics, Inc.盘中异动 早盘大幅上涨5.02%报30.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431865610","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431865610?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:37","pubTimestamp":1714397844,"startTime":"0","endTime":"0","summary":"北京时间2024年04月29日21时37分，Ptc Therapeutics, Inc.股票出现波动，股价快速上涨5.02%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。其相关个股中，Soleno Therapeutics, Inc.、Immunitybio, Inc.、Zyversa Therapeutics, Inc.涨幅较大，Zyversa Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Avenue Therapeutics, Inc.较为活跃，换手率分别为534.87%、24.27%、12.03%，振幅较大的相关个股有Cassava Sciences Inc C/Wts 15/11/2024、Zyversa Therapeutics, Inc.、Soleno Therapeutics, Inc.，振幅分别为28.57%、17.43%、14.62%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292137247a5728b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292137247a5728b3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430927739","title":"Ptc Therapeutics, Inc.盘中异动 大幅上涨5.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430927739","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430927739?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:31","pubTimestamp":1714138273,"startTime":"0","endTime":"0","summary":"北京时间2024年04月26日21时31分，Ptc Therapeutics, Inc.股票出现波动，股价急速拉升5.88%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.50%。其相关个股中，Biodexa Pharmaceuticals Plc、Cassava Sciences Inc C/Wts 15/11/2024、Tevogen Bio Holdings Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Kintara Therapeutics, Inc.、Processa Pharmaceuticals, Inc.较为活跃，换手率分别为491.84%、67.35%、19.66%，振幅较大的相关个股有Cassava Sciences Inc C/Wts 15/11/2024、Biodexa Pharmaceuticals Plc、Allarity Therapeutics, Inc.，振幅分别为34.80%、20.70%、18.81%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621311387b3f028&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621311387b3f028&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429777147","title":"PTC Therapeutics Inc    预计每股亏损 1.24 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429777147","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429777147?lang=zh_cn&edition=full","pubTime":"2024-04-24 04:53","pubTimestamp":1713905603,"startTime":"0","endTime":"0","summary":"   * PTC Therapeutics Inc     将于4月25日公布截至2024年3月31日的财报，预计该公司的季度收入将出现下降。* 根据LSEG的数据，11位分析师的平均预期显示，这家总部位于新泽西州沃伦的公司的营收将从去年同期的2.2038亿美元降至1.69703亿美元，降幅为23.0%。* LSEG 分析师对 PTC Therapeutics Inc 的平均预期是每股亏损 1.24 美元。* 华尔街对 PTC Therapeutics Inc 的 12 个月目标价中值为 28.00 美元，高于其上次收盘价 25.97 美元。4月23日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426989735","title":"坎托菲茨杰拉德公司：重申PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价45.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426989735","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426989735?lang=zh_cn&edition=full","pubTime":"2024-04-12 22:05","pubTimestamp":1712930734,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412220540876f713f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412220540876f713f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420798966","title":"美国研究综述-迪克体育用品、Nvidia、PVH","url":"https://stock-news.laohu8.com/highlight/detail?id=2420798966","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420798966?lang=zh_cn&edition=full","pubTime":"2024-03-20 15:14","pubTimestamp":1710918896,"startTime":"0","endTime":"0","summary":"    路透社3月20日 - 华尔街证券分析师周三调整了对迪克体育用品公司、英伟达和 PVH 等几家美国上市公司的评级和目标价。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416466531","title":"美国研究综述-Broadcom、纽约社区银行、TopBuild","url":"https://stock-news.laohu8.com/highlight/detail?id=2416466531","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2416466531?lang=zh_cn&edition=full","pubTime":"2024-03-01 14:50","pubTimestamp":1709275809,"startTime":"0","endTime":"0","summary":"    路透社3月1日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括博通公司、纽约社区银行和 TopBuild。要闻             * 博通公司  ：奥本海默将目标价从1100美元上调至1500美元              * 纽约社区银行  ：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。* TopBuild Corp   ：Benchmark将目标价从320美元上调至450美元  以下是路透社周五报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412611303","title":"PTC Therapeutics Inc    预计每股收益 53 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2412611303","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412611303?lang=zh_cn&edition=full","pubTime":"2024-02-17 06:14","pubTimestamp":1708121656,"startTime":"0","endTime":"0","summary":"   * PTC Therapeutics Inc     将于2月29日公布截至2023年12月31日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，12位分析师的平均预期显示，这家总部位于新泽西州南普兰菲尔德的公司预计将实现91.2%的营收增长，从去年同期的1.6741亿美元增至3.2095亿美元。* LSEG 分析师对 PTC Therapeutics Inc 的平均预期为每股收益 53 美分。* 华尔街对 PTC Therapeutics Inc 的 12 个月目标价中位数为 25.00 美元，低于其上次收盘价 25.69 美元。2月16日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2406796509","title":"Ptc Therapeutics Inc盘中异动 早盘大幅跳水5.10%报25.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2406796509","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2406796509?lang=zh_cn&edition=full","pubTime":"2024-01-26 22:33","pubTimestamp":1706279621,"startTime":"0","endTime":"0","summary":"北京时间2024年01月26日22时33分，Ptc Therapeutics Inc股票出现波动，股价急速跳水5.10%。截至发稿，该股报25.30美元/股，成交量17.8262万股，换手率0.24%，振幅2.25%。Ptc Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.65%。Ptc Therapeutics Inc公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240126223342790c7e57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240126223342790c7e57&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2406579879","title":"BUZZ-PTC Therapeutics因欧洲将下架其肌肉失调药物而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2406579879","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2406579879?lang=zh_cn&edition=full","pubTime":"2024-01-26 22:04","pubTimestamp":1706277895,"startTime":"0","endTime":"0","summary":"    1月26日 - ** 制药商PTC Therapeutics   股价盘前下跌约10%，至  $24** 周四晚些时候，欧洲卫生监管机构的顾问小组重申了对该公司肌肉失调药物 。** 欧洲委员会将批准该意见，并在 67 天内将该药撤出市场。** 这种名为Translarna的药物于2014年在欧洲获得有条件批准，用于治疗五岁及以上患有杜兴氏肌肉萎缩症的儿童，这种疾病是一种遗传性进行性肌肉萎缩疾病。** Translarna旨在促进一种名为 \"肌营养不良蛋白\"的蛋白质的生产，缺乏这种蛋白质会导致DMD患者肌肉衰弱。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2406922018","title":"更新版 1-欧洲将撤回 PTC Therapeutics 的罕见肌肉疾病药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2406922018","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2406922018?lang=zh_cn&edition=full","pubTime":"2024-01-26 05:52","pubTimestamp":1706219526,"startTime":"0","endTime":"0","summary":"     路透1月25日 - PTC Therapeutics   周四称，欧洲卫生监管机构的顾问小组对其治疗一种遗传性进行性肌肉萎缩症的药物发表了否定意见，导致其股价在盘后交易中下跌近12%。这种名为 Translarna 的药物旨在治疗杜兴氏肌肉萎缩症，这是一种导致肌肉退化的遗传性疾病，几乎总是影响年轻男孩。该公司表示，人用医药产品委员会发表的否定意见将导致该疗法在欧洲的撤消。据美国国家罕见疾病组织称，估计全球每 3500 名男婴中就有一名患有 DMD。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2406222187","title":"PTC Therapeutics的肌肉失调药物未能获得欧盟监管机构的支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2406222187","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2406222187?lang=zh_cn&edition=full","pubTime":"2024-01-26 05:20","pubTimestamp":1706217606,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透1月25日 - 欧洲卫生监管机构顾问小组周四表示，对PTC Therapeutics公司治疗杜兴氏肌肉萎缩症（Duchenne muscular dystrophy(DMD)）的  药物持否定意见，这是一种遗传性进行性肌肉萎缩疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ptcbio.com","stockEarnings":[{"period":"1week","weight":-0.0884},{"period":"1month","weight":0.1585},{"period":"3month","weight":0.2333},{"period":"6month","weight":0.6796},{"period":"1year","weight":-0.4433},{"period":"ytd","weight":0.1299}],"compareEarnings":[{"period":"1week","weight":0.0337},{"period":"1month","weight":-0.0029},{"period":"3month","weight":0.0379},{"period":"6month","weight":0.1738},{"period":"1year","weight":0.2586},{"period":"ytd","weight":0.0881}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ptc Therapeutics, Inc.于1998年3月31日注册成立为一家特拉华州公司。 PTC Therapeutics股份有限公司是一家生物制药公司，专注于用于转录后控制过程中的口服药，专有的小分子药物的发现和开发。同时该公司的研发计划针对于多个治疗领域，公司特别专注于孤儿和超孤儿混乱疾病的治疗的开发和商业化。公司主导的候选产品是ataluren，该产品用于治疗过程中所出现的一种被称为无义突变基因突变的遗传性疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.108578},{"month":2,"riseRate":0.545455,"avgChangeRate":-0.006897},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.072507},{"month":4,"riseRate":0.545455,"avgChangeRate":0.029187},{"month":5,"riseRate":0.454545,"avgChangeRate":0.012468},{"month":6,"riseRate":0.6,"avgChangeRate":0.078138},{"month":7,"riseRate":0.6,"avgChangeRate":0.014806},{"month":8,"riseRate":0.727273,"avgChangeRate":0.074942},{"month":9,"riseRate":0.454545,"avgChangeRate":0.019267},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.105915},{"month":11,"riseRate":0.636364,"avgChangeRate":0.126397},{"month":12,"riseRate":0.636364,"avgChangeRate":0.045178}],"exchange":"NASDAQ","name":"PTC Therapeutics Inc.","nameEN":"PTC Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PTC Therapeutics Inc.,PTCT,PTC Therapeutics Inc.股票,PTC Therapeutics Inc.股票老虎,PTC Therapeutics Inc.股票老虎国际,PTC Therapeutics Inc.行情,PTC Therapeutics Inc.股票行情,PTC Therapeutics Inc.股价,PTC Therapeutics Inc.股市,PTC Therapeutics Inc.股票价格,PTC Therapeutics Inc.股票交易,PTC Therapeutics Inc.股票购买,PTC Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}